Evidence map›Paper›PMID 38193116›Full record

ArticleBioengineering & translational medicine2024

Rapid, label-free enrichment of lymphocytes in a closed system using a flow-through microfluidic device.

Anton Mukhamedshin, Riley C Reddington, Mai T P Dinh, Kumar Abhishek, Mubasher Iqbal, Marc Manheim, Sean C Gifford, Sergey S Shevkoplyas

Open access · goldAbstract read
In one paragraph

Article in Bioengineering & translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Anton MukhamedshinDepartment of Biomedical Engineering University of Houston Houston Texas USA.
Riley C ReddingtonHalcyon Biomedical, Incorporated Friendswood Texas USA.
Mai T P DinhDepartment of Biomedical Engineering University of Houston Houston Texas USA.
Kumar AbhishekDepartment of Biomedical Engineering University of Houston Houston Texas USA.
Mubasher IqbalDepartment of Biomedical Engineering University of Houston Houston Texas USA.
Marc ManheimHalcyon Biomedical, Incorporated Friendswood Texas USA.
Sean C GiffordHalcyon Biomedical, Incorporated Friendswood Texas USA.
Sergey S ShevkoplyasDepartment of Biomedical Engineering University of Houston Houston Texas USA.ORCID https://orcid.org/0000-0002-8203-8365
University of Houston · USHalcyon Biomedical (United States) · US

Funding

Enabling pediatric leukapheresis with high-throughput microfluidic technologyR01HL151858 · NHLBI · UNIVERSITY OF HOUSTON · PI SHEVKOPLYAS, SERGEY S · 2020 to 2023
$1.6M
NHLBI NIH HHS R01 HL151858
6 · The paper itself

Abstract

The majority of adoptive cellular therapies are produced from peripheral mononuclear cells obtained via leukapheresis and further enriched for the cells of interest (e.g., T cells). Here, we present a first-of-its-kind closed system, which effectively removes ~85% of monocytes and ~88% of platelets, while recovering ~88% of concentrated T cells in a separate output stream, as the leukapheresis sample flows through a microfluidic device at 5 mL/min. The system is driven by a common peristaltic pump, enabled by a novel pressure wave dampener, and operates in a closed bag-to-bag configuration, without requiring any specialized, dedicated equipment. When compared to standard density gradient centrifugation on paired samples, the new system demonstrated a 1.5-fold increase in T cell recovery and a 2-fold reduction in inter-sample variability for this separation outcome. The T cell-to-monocyte ratio of the leukapheresis sample was increased to 20:1, whereas with density gradient processing it decreased to 2:1. As a result of superior purity and/or gentler processing, T cells enriched by the system showed a 2.7-times higher fold expansion during subsequent culture, and an overall 3.5-times higher cumulative yield. This centrifugation-free and label-free closed system for enriching lymphocytes could significantly simplify and standardize the manufacturing of life-saving cellular therapies.

Indexed as

cell separationcellular therapyleukapheresislymphocytesmicrofluidics

Identifiers

PMID38193116
PMCPMC10771558
OpenAlexW4387058403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.